In clinical trials
Immune & defense
Nangibotide
Evidence
Clinical trials
Class
TREM-1 inhibitor peptide
KEY TAKEAWAY
Nangibotide is a 12-amino-acid peptide that blocks TREM-1, a receptor that amplifies inflammation during infection. Inotrem is developing it for septic shock. Nangibotide is not FDA-approved and has been tested in phase 2 and phase 3 trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
TREM-1 inhibitor peptide
Being studied for
Studied in septic shock
Key fact
Nangibotide is not FDA-approved and has been tested in phase 2 and phase 3 trials.
Route
Intravenous infusion in trials
Evidence strength
Clinical trials
Nangibotide is a 12-amino-acid peptide that blocks TREM-1, a receptor that amplifies inflammation during infection. Inotrem is developing it for septic shock.
By limiting TREM-1 signaling, it aims to calm the overactive immune response that damages organs in sepsis.
Nangibotide is not FDA-approved and has been tested in phase 2 and phase 3 trials.
Studied in septic shock.
Trials in critically ill patients reported adverse events at rates similar to placebo, but data are still being evaluated.
Nangibotide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.